Difficulty: Medium
Average Score: 62%
Practice
Tick the estrogen inhibitor:
Correct answer
B
Rationale
In the context of advanced pharmacology across the lifespan, understanding estrogen inhibitors is crucial for the management of various conditions such as breast cancer and hormonal disorders. Among the options provided, Tamoxifen (Option B) is the correct estrogen inhibitor to tick.
Tamoxifen is a selective estrogen receptor modulator (SERM) that competes with estrogen for binding sites on estrogen receptors in target tissues. It acts as an estrogen antagonist in the breast tissue, making it a valuable medication in the treatment and prevention of estrogen receptor-positive breast cancer.
Leuprolide (Option A) is a gonadotropin-releasing hormone (GnRH) agonist that works by initially stimulating the release of gonadotropins but ultimately suppresses gonadotropin secretion, leading to decreased estrogen and testosterone production.
Flutamide (Option C) is an androgen receptor antagonist primarily used in the treatment of prostate cancer by blocking the effects of androgens like testosterone.
Anastrozole (Option D) is an aromatase inhibitor that works by inhibiting the enzyme aromatase, which is responsible for the conversion of androgens to estrogens. It is used in the treatment of estrogen receptor-positive breast cancer in postmenopausal women.
Educationally, understanding the mechanisms of action of different estrogen inhibitors is essential for pharmacology students and healthcare professionals to make informed decisions regarding drug selection, dosing, and monitoring in clinical practice. It also underscores the importance of personalized medicine in tailoring treatment options to individual patient needs and characteristics.
Tamoxifen is a selective estrogen receptor modulator (SERM) that competes with estrogen for binding sites on estrogen receptors in target tissues. It acts as an estrogen antagonist in the breast tissue, making it a valuable medication in the treatment and prevention of estrogen receptor-positive breast cancer.
Leuprolide (Option A) is a gonadotropin-releasing hormone (GnRH) agonist that works by initially stimulating the release of gonadotropins but ultimately suppresses gonadotropin secretion, leading to decreased estrogen and testosterone production.
Flutamide (Option C) is an androgen receptor antagonist primarily used in the treatment of prostate cancer by blocking the effects of androgens like testosterone.
Anastrozole (Option D) is an aromatase inhibitor that works by inhibiting the enzyme aromatase, which is responsible for the conversion of androgens to estrogens. It is used in the treatment of estrogen receptor-positive breast cancer in postmenopausal women.
Educationally, understanding the mechanisms of action of different estrogen inhibitors is essential for pharmacology students and healthcare professionals to make informed decisions regarding drug selection, dosing, and monitoring in clinical practice. It also underscores the importance of personalized medicine in tailoring treatment options to individual patient needs and characteristics.